{"title":"通过Rac1/NF-κB/MMP2信号通路的迁移和侵袭促进凋亡，从而抑制子宫内膜癌细胞增殖","authors":"","doi":"10.1007/s12257-024-00088-4","DOIUrl":null,"url":null,"abstract":"<span> <h3>Abstract</h3> <p>Endometrial carcinoma affects the uterine lining. Endogenous activity, intrinsic targeting, and ability to engage with a host defence system make exosomal vehicles (EVs) a viable cancer treatment alternative. Due to these benefits, mesenchymal stem cell (MSC)-derived EVs loaded with carboplatin and paclitaxel could resemble immune cells to fight cancer. This study found that Car-Pac@EVs downregulated endometrial cancer (EC) cells relative to normal endometrium. Car-Pac@EVs' effects on ECC-1 and HEC-1A EC cells at different doses were examined in vitro. To detect cancer, MTT, flow cytometry, and transwell assays were used. Protein expression was measured by Western blotting and qRT-PCR. Car-Pac@EVs were affected by time- and dose-dependent EC cell proliferation reductions. In EC cells, Car-Pac@EVs triggered apoptosis. Car-Pac@EVs formulation reduced EC cell migration and invasion by reducing MMP-2 expression via Rac1/NF-κB signalling. The results indicated that Car-Pac@EVs may be an effective EC diagnosis and treatment target.</p> </span> <span> <h3>Graphical abstract</h3> <p><span> <span> <img alt=\"\" src=\"https://static-content.springer.com/image/MediaObjects/12257_2024_88_Figa_HTML.png\"/> </span> </span></p> </span>","PeriodicalId":8936,"journal":{"name":"Biotechnology and Bioprocess Engineering","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Dual-drug-loaded MSCs-derived exosomal vesicles inhibit endometrial cancer cell proliferation by promoting apoptosis through the migration and invasion of Rac1/NF-κB/MMP2 signalling pathway\",\"authors\":\"\",\"doi\":\"10.1007/s12257-024-00088-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<span> <h3>Abstract</h3> <p>Endometrial carcinoma affects the uterine lining. Endogenous activity, intrinsic targeting, and ability to engage with a host defence system make exosomal vehicles (EVs) a viable cancer treatment alternative. Due to these benefits, mesenchymal stem cell (MSC)-derived EVs loaded with carboplatin and paclitaxel could resemble immune cells to fight cancer. This study found that Car-Pac@EVs downregulated endometrial cancer (EC) cells relative to normal endometrium. Car-Pac@EVs' effects on ECC-1 and HEC-1A EC cells at different doses were examined in vitro. To detect cancer, MTT, flow cytometry, and transwell assays were used. Protein expression was measured by Western blotting and qRT-PCR. Car-Pac@EVs were affected by time- and dose-dependent EC cell proliferation reductions. In EC cells, Car-Pac@EVs triggered apoptosis. Car-Pac@EVs formulation reduced EC cell migration and invasion by reducing MMP-2 expression via Rac1/NF-κB signalling. The results indicated that Car-Pac@EVs may be an effective EC diagnosis and treatment target.</p> </span> <span> <h3>Graphical abstract</h3> <p><span> <span> <img alt=\\\"\\\" src=\\\"https://static-content.springer.com/image/MediaObjects/12257_2024_88_Figa_HTML.png\\\"/> </span> </span></p> </span>\",\"PeriodicalId\":8936,\"journal\":{\"name\":\"Biotechnology and Bioprocess Engineering\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-03-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biotechnology and Bioprocess Engineering\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.1007/s12257-024-00088-4\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnology and Bioprocess Engineering","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1007/s12257-024-00088-4","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
Dual-drug-loaded MSCs-derived exosomal vesicles inhibit endometrial cancer cell proliferation by promoting apoptosis through the migration and invasion of Rac1/NF-κB/MMP2 signalling pathway
Abstract
Endometrial carcinoma affects the uterine lining. Endogenous activity, intrinsic targeting, and ability to engage with a host defence system make exosomal vehicles (EVs) a viable cancer treatment alternative. Due to these benefits, mesenchymal stem cell (MSC)-derived EVs loaded with carboplatin and paclitaxel could resemble immune cells to fight cancer. This study found that Car-Pac@EVs downregulated endometrial cancer (EC) cells relative to normal endometrium. Car-Pac@EVs' effects on ECC-1 and HEC-1A EC cells at different doses were examined in vitro. To detect cancer, MTT, flow cytometry, and transwell assays were used. Protein expression was measured by Western blotting and qRT-PCR. Car-Pac@EVs were affected by time- and dose-dependent EC cell proliferation reductions. In EC cells, Car-Pac@EVs triggered apoptosis. Car-Pac@EVs formulation reduced EC cell migration and invasion by reducing MMP-2 expression via Rac1/NF-κB signalling. The results indicated that Car-Pac@EVs may be an effective EC diagnosis and treatment target.
期刊介绍：
Biotechnology and Bioprocess Engineering is an international bimonthly journal published by the Korean Society for Biotechnology and Bioengineering. BBE is devoted to the advancement in science and technology in the wide area of biotechnology, bioengineering, and (bio)medical engineering. This includes but is not limited to applied molecular and cell biology, engineered biocatalysis and biotransformation, metabolic engineering and systems biology, bioseparation and bioprocess engineering, cell culture technology, environmental and food biotechnology, pharmaceutics and biopharmaceutics, biomaterials engineering, nanobiotechnology, and biosensor and bioelectronics.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
